Acrivon Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
ACRV$1.57-0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Common Stock | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | AdditionalPaid-InCapital | AccumulatedOtherComprehensiveIncome (Loss) | AccumulatedDeficit | TotalStockholders’Equity | |
| Balance at December 31, 2024 | 31,231,264 | $31 | $373,284 | $447 | $(196,976) | $176,786 |
| Exercise of common stock options | 225 | — | 1 | — | — | 1 |
| Issuance of common stock upon vesting of restricted stock units, net of shares withheld for tax | 120,578 | — | (344) | — | — | (344) |
| Stock-based compensation expense | — | — | 3,791 | — | — | 3,791 |
| Unrealized loss on available-for-sale investments, net of tax | — | — | — | (164) | — | (164) |
| Net loss | — | — | — | — | (19,680) | (19,680) |
| Balance at March 31, 2025 | 31,352,067 | $31 | $376,732 | $283 | $(216,656) | $160,390 |
| Common Stock | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | AdditionalPaid-InCapital | AccumulatedOtherComprehensiveIncome (Loss) | AccumulatedDeficit | TotalStockholders’Equity | |
| Balance at December 31, 2023 | 22,522,644 | $23 | $237,675 | $(83) | $(116,420) | $121,195 |
| Exercise of common stock options | 20,277 | — | 79 | — | — | 79 |
| Issuance of common stock upon vesting of restricted stock units, net of shares withheld for tax | 94,618 | — | (166) | — | — | (166) |
| Stock-based compensation expense | — | — | 3,344 | — | — | 3,344 |
| Unrealized gain on available-for-sale investments, net of tax | — | — | — | 13 | — | 13 |
| Net loss | — | — | — | — | (16,486) | (16,486) |
| Balance at March 31, 2024 | 22,637,539 | $23 | $240,932 | $(70) | $(132,906) | $107,979 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.